216 related articles for article (PubMed ID: 24698059)
21. [Orphan drugs: drugs for rare diseases].
Schenk M
Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
[No Abstract] [Full Text] [Related]
22. [Conference 1. An economic observatory for orphan drugs: myth or reality?].
Duguet C; Ferry A
Med Sci (Paris); 2014 Apr; 30 Spe(1):21-3. PubMed ID: 24755173
[No Abstract] [Full Text] [Related]
23. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
24. Issues surrounding orphan disease and orphan drug policies in Europe.
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
[TBL] [Abstract][Full Text] [Related]
25. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases.
Largent EA; Pearson SD
Hastings Cent Rep; 2012; 42(1):27-34. PubMed ID: 22616398
[No Abstract] [Full Text] [Related]
26. Pricing of orphan drugs.
Leonard JV; Richmond S
Lancet; 2009 Feb; 373(9662):462. PubMed ID: 19200917
[No Abstract] [Full Text] [Related]
27. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
John JE
Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
[No Abstract] [Full Text] [Related]
28. Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness.
Sheehan M
BMJ; 2005 Nov; 331(7525):1144-5. PubMed ID: 16282416
[No Abstract] [Full Text] [Related]
29. Reducing the cost of rare disease drugs.
Lancet; 2015 Feb; 385(9970):746. PubMed ID: 25752156
[No Abstract] [Full Text] [Related]
30. MSJAMA: Orphan diseases and adoptive initiatives.
Iribarne A
JAMA; 2003 Jul; 290(1):116. PubMed ID: 12837724
[No Abstract] [Full Text] [Related]
31. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.
Schlander M; Adarkwah CC; Gandjour A
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):171-9. PubMed ID: 25312018
[TBL] [Abstract][Full Text] [Related]
32. Management of rare diseases.
Walshe JM
QJM; 2006 Feb; 99(2):123-4. PubMed ID: 16428334
[No Abstract] [Full Text] [Related]
33. Orphan drugs and the NHS: should we value rarity?
McCabe C; Claxton K; Tsuchiya A
BMJ; 2005 Oct; 331(7523):1016-9. PubMed ID: 16254305
[TBL] [Abstract][Full Text] [Related]
34. Regulators adopt more orphan drugs.
Reardon S
Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
[No Abstract] [Full Text] [Related]
35. Drugs for rare diseases: influence of orphan designation status on price.
Picavet E; Dooms M; Cassiman D; Simoens S
Appl Health Econ Health Policy; 2011 Jul; 9(4):275-9. PubMed ID: 21682354
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum.
Simoens S; Picavet E; Dooms M; Cassiman D; Morel T
Appl Health Econ Health Policy; 2013 Feb; 11(1):1-3. PubMed ID: 23329382
[No Abstract] [Full Text] [Related]
37. EU to review rare disease drugs market exclusivity.
Sheridan C
Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
[No Abstract] [Full Text] [Related]
38. Rare diseases: the bane of modern society and the quest for cures.
Azie N; Vincent J
Clin Pharmacol Ther; 2012 Aug; 92(2):135-9. PubMed ID: 22814654
[TBL] [Abstract][Full Text] [Related]
39. Does orphan drug legislation really answer the needs of patients?
Haffner ME; Torrent-Farnell J; Maher PD
Lancet; 2008 Jun; 371(9629):2041-4. PubMed ID: 18555916
[No Abstract] [Full Text] [Related]
40. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
Pariser AR; Xu K; Milto J; Coté TR
Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
